Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) had its price objective lowered by Bank of America from $14.00 to $12.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Bank of America‘s price target indicates a potential upside of 128.57% from the […]

Leave a Reply

Your email address will not be published.

Previous post ThredUp’s (TDUP) “Outperform” Rating Reiterated at Telsey Advisory Group
Next post Zai Lab (NASDAQ:ZLAB) Upgraded at Cantor Fitzgerald